Here are the 10-K annual reports from Actuate Therapeutics, Inc. (ACTU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ACTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACTU filings page.
Actuate Therapeutics’ Annual Report focuses on elraglusib, its lead GSK‑3β inhibitor, and strong Phase 2 data in metastatic pancreatic ductal adenocarcinoma (mPDAC). In a 286‑patient trial, elraglusib plus gemcitabine/nab‑paclitaxel achieved median overall survival of 10.1 months versus 7.2 months on chemotherapy alone (hazard ratio 0.62, p=0.02).
The 12‑month survival rate nearly doubled to 44.4% from 22.3%, with 24‑month survival rising to 12.9% from 2.6%, while safety was broadly consistent with the control arm. The company is planning Phase 3 global registration discussions with the FDA and EMA and is also advancing elraglusib in pediatric cancers and developing a highly bioavailable oral tablet for additional solid tumor indications.
Actuate remains a clinical‑stage company with no approved products, significant ongoing losses, and a need for substantial additional capital. As of June 30, 2025, non‑affiliate market value was about $42.1 million, and 23,709,943 shares were outstanding as of March 25, 2026.